IP Verse

Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof - EP3105331

The patent EP3105331 was granted to Alnylam Pharmaceuticals on Jun 23, 2021. The application was originally filed on Feb 11, 2015 under application number EP15705888A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3105331

ALNYLAM PHARMACEUTICALS
Application Number
EP15705888A
Filing Date
Feb 11, 2015
Status
Granted And Under Opposition
May 21, 2021
Grant Date
Jun 23, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBMar 23, 2022GRUNECKER PATENT -

Patent Citations (297) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20080018611
DESCRIPTIONUS20080018616
DESCRIPTIONUS20080039748
DESCRIPTIONUS20080047087
DESCRIPTIONUS20080051528
DESCRIPTIONUS20080056230
DESCRIPTIONUS20080107998
DESCRIPTIONWO2007US80331
DESCRIPTIONWO2009US63933
DESCRIPTIONWO2010US22614
DESCRIPTIONWO2010US33777
DESCRIPTIONWO2012US65691
DESCRIPTIONUS2003027780
DESCRIPTIONUS2003144217
DESCRIPTIONUS2004127488
DESCRIPTIONUS2004167116
DESCRIPTIONUS2004171570
DESCRIPTIONUS2005148548
DESCRIPTIONUS2005281781
DESCRIPTIONUS2008039618
DESCRIPTIONUS2009012281
DESCRIPTIONUS2010324120
DESCRIPTIONUS2011313020
DESCRIPTIONUS2013011922
DESCRIPTIONUS2013096289
DESCRIPTIONUS2013190383
DESCRIPTIONUS3687808
DESCRIPTIONUS4469863
DESCRIPTIONUS4476301
DESCRIPTIONUS4587044
DESCRIPTIONUS4605735
DESCRIPTIONUS4667025
DESCRIPTIONUS4762779
DESCRIPTIONUS4789737
DESCRIPTIONUS4824941
DESCRIPTIONUS4828979
DESCRIPTIONUS4835263
DESCRIPTIONUS4837028
DESCRIPTIONUS4845205
DESCRIPTIONUS4876335
DESCRIPTIONUS4897355
DESCRIPTIONUS4904582
DESCRIPTIONUS4948882
DESCRIPTIONUS4958013
DESCRIPTIONUS4981957
DESCRIPTIONUS5023243
DESCRIPTIONUS5032401
DESCRIPTIONUS5034506
DESCRIPTIONUS5082830
DESCRIPTIONUS5109124
DESCRIPTIONUS5112963
DESCRIPTIONUS5118800
DESCRIPTIONUS5118802
DESCRIPTIONUS513030
DESCRIPTIONUS5134066
DESCRIPTIONUS5138045
DESCRIPTIONUS5139941
DESCRIPTIONUS5166315
DESCRIPTIONUS5171678
DESCRIPTIONUS5175273
DESCRIPTIONUS5177195
DESCRIPTIONUS5185444
DESCRIPTIONUS5188897
DESCRIPTIONUS5214134
DESCRIPTIONUS5214136
DESCRIPTIONUS5216141
DESCRIPTIONUS5218105
DESCRIPTIONUS5235033
DESCRIPTIONUS5245022
DESCRIPTIONUS5252479
DESCRIPTIONUS5254469
DESCRIPTIONUS5258506
DESCRIPTIONUS5262536
DESCRIPTIONUS5264423
DESCRIPTIONUS5264564
DESCRIPTIONUS5272250
DESCRIPTIONUS5276019
DESCRIPTIONUS5278302
DESCRIPTIONUS5283185
DESCRIPTIONUS5286717
DESCRIPTIONUS5292873
DESCRIPTIONUS5317098
DESCRIPTIONUS5319080
DESCRIPTIONUS5321131
DESCRIPTIONUS5359044
DESCRIPTIONUS5367066
DESCRIPTIONUS5371241
DESCRIPTIONUS5391723
DESCRIPTIONUS5393878
DESCRIPTIONUS5399676
DESCRIPTIONUS5405938
DESCRIPTIONUS5405939
DESCRIPTIONUS5414077
DESCRIPTIONUS5416203
DESCRIPTIONUS5432272
DESCRIPTIONUS5434257
DESCRIPTIONUS5436146
DESCRIPTIONUS5446137
DESCRIPTIONUS5451463
DESCRIPTIONUS5453496
DESCRIPTIONUS5455233
DESCRIPTIONUS5457187
DESCRIPTIONUS5459255
DESCRIPTIONUS5466677
DESCRIPTIONUS5466786
DESCRIPTIONUS5470967
DESCRIPTIONUS5476925
DESCRIPTIONUS5484908
DESCRIPTIONUS5486603
DESCRIPTIONUS5489677
DESCRIPTIONUS5502177
DESCRIPTIONUS5510475
DESCRIPTIONUS5512439
DESCRIPTIONUS5512667
DESCRIPTIONUS5514785
DESCRIPTIONUS5519126
DESCRIPTIONUS5519134
DESCRIPTIONUS5525465
DESCRIPTIONUS5525711
DESCRIPTIONUS5536821
DESCRIPTIONUS5539082
DESCRIPTIONUS5541307
DESCRIPTIONUS5541313
DESCRIPTIONUS5541316
DESCRIPTIONUS5543152
DESCRIPTIONUS5545730
DESCRIPTIONUS5550111
DESCRIPTIONUS5552538
DESCRIPTIONUS5552540
DESCRIPTIONUS5561225
DESCRIPTIONUS5563253
DESCRIPTIONUS5565552
DESCRIPTIONUS5567810
DESCRIPTIONUS5567811
DESCRIPTIONUS5571799
DESCRIPTIONUS5574142
DESCRIPTIONUS5576427
DESCRIPTIONUS5578717
DESCRIPTIONUS5578718
DESCRIPTIONUS5580731
DESCRIPTIONUS5585481
DESCRIPTIONUS5587361
DESCRIPTIONUS5587371
DESCRIPTIONUS5587469
DESCRIPTIONUS5591584
DESCRIPTIONUS5591722
DESCRIPTIONUS5594121
DESCRIPTIONUS5595726
DESCRIPTIONUS5596086
DESCRIPTIONUS5596091
DESCRIPTIONUS5597696
DESCRIPTIONUS5597909
DESCRIPTIONUS5599923
DESCRIPTIONUS5599928
DESCRIPTIONUS5602240
DESCRIPTIONUS5607677
DESCRIPTIONUS5608046
DESCRIPTIONUS5610289
DESCRIPTIONUS5610300
DESCRIPTIONUS5614617
DESCRIPTIONUS5618704
DESCRIPTIONUS5623070
DESCRIPTIONUS5625050
DESCRIPTIONUS5627053
DESCRIPTIONUS5633360
DESCRIPTIONUS5639873
DESCRIPTIONUS564562
DESCRIPTIONUS5646265
DESCRIPTIONUS5658873
DESCRIPTIONUS5663312
DESCRIPTIONUS5665557
DESCRIPTIONUS5670633
DESCRIPTIONUS5677437
DESCRIPTIONUS5677439
DESCRIPTIONUS5681941
DESCRIPTIONUS5688941
DESCRIPTIONUS5700920
DESCRIPTIONUS5705188
DESCRIPTIONUS5714331
DESCRIPTIONUS5719262
DESCRIPTIONUS5750692
DESCRIPTIONUS5976567
DESCRIPTIONUS5981276
DESCRIPTIONUS5981501
DESCRIPTIONUS6015886
DESCRIPTIONUS6028188
DESCRIPTIONUS6054299
DESCRIPTIONUS6124445
DESCRIPTIONUS6143520
DESCRIPTIONUS6147200
DESCRIPTIONUS6160109
DESCRIPTIONUS6166197
DESCRIPTIONUS6169170
DESCRIPTIONUS6172209
DESCRIPTIONUS6191105
DESCRIPTIONUS6222025
DESCRIPTIONUS6235887
DESCRIPTIONUS6239265
DESCRIPTIONUS6268490
DESCRIPTIONUS6277603
DESCRIPTIONUS6294664
DESCRIPTIONUS6320017
DESCRIPTIONUS6326199
DESCRIPTIONUS6346614
DESCRIPTIONUS6380368
DESCRIPTIONUS6444423
DESCRIPTIONUS6525191
DESCRIPTIONUS6528640
DESCRIPTIONUS6531590
DESCRIPTIONUS6534484
DESCRIPTIONUS6534639
DESCRIPTIONUS6576752
DESCRIPTIONUS6586410
DESCRIPTIONUS6608035
DESCRIPTIONUS6617438
DESCRIPTIONUS6639062
DESCRIPTIONUS6670461
DESCRIPTIONUS6683167
DESCRIPTIONUS6747014
DESCRIPTIONUS6770748
DESCRIPTIONUS6783931
DESCRIPTIONUS6794499
DESCRIPTIONUS6815432
DESCRIPTIONUS6858225
DESCRIPTIONUS6858715
DESCRIPTIONUS6867294
DESCRIPTIONUS6878805
DESCRIPTIONUS6887906
DESCRIPTIONUS6900297
DESCRIPTIONUS6998484
DESCRIPTIONUS7015315
DESCRIPTIONUS7034133
DESCRIPTIONUS7037646
DESCRIPTIONUS7041816
DESCRIPTIONUS7045610
DESCRIPTIONUS7053207
DESCRIPTIONUS7063860
DESCRIPTIONUS7070802
DESCRIPTIONUS7084125
DESCRIPTIONUS7157099
DESCRIPTIONUS7273933
DESCRIPTIONUS7321029
DESCRIPTIONUS7399845
DESCRIPTIONUS7427605
DESCRIPTIONUS7427672
DESCRIPTIONUS7495088
DESCRIPTIONUS7569686
DESCRIPTIONUS7741457
DESCRIPTIONUS7858769
DESCRIPTIONUS8022193
DESCRIPTIONUS8030467
DESCRIPTIONUS8058069
DESCRIPTIONUS8101348
DESCRIPTIONUS8106022
DESCRIPTIONUS8158601
DESCRIPTIONUS8278283
DESCRIPTIONUS8278425
DESCRIPTIONUS8278426
DESCRIPTIONUS8314227
DESCRIPTIONUSRE39464E
DESCRIPTIONWO0003683
DESCRIPTIONWO0022113
DESCRIPTIONWO0022114
DESCRIPTIONWO2007091269
DESCRIPTIONWO2007117686
DESCRIPTIONWO2008042973
DESCRIPTIONWO2009014887
DESCRIPTIONWO2009127060
DESCRIPTIONWO2010141511
DESCRIPTIONWO2011005861
DESCRIPTIONWO2011031520
DESCRIPTIONWO2013036868
DESCRIPTIONWO2014179620
DESCRIPTIONWO2014179627
DESCRIPTIONWO8804924
DESCRIPTIONWO9116024
DESCRIPTIONWO9324640
DESCRIPTIONWO9324641
DESCRIPTIONWO9400569
DESCRIPTIONWO9402595
DESCRIPTIONWO9412649
DESCRIPTIONWO9413788
DESCRIPTIONWO9637194
DESCRIPTIONWO9640964
DESCRIPTIONWO9713499
DESCRIPTIONWO9730731
DESCRIPTIONWO9839359
DESCRIPTIONWO9914226
EXAMINATIONEP1752536
INTERNATIONAL-SEARCH-REPORTWO2012019188
OPPOSITIONEP1752536
OPPOSITIONUS2005032733
OPPOSITIONUS2005255487
OPPOSITIONWO2004015107
OPPOSITIONWO2005089224
OPPOSITIONWO2012019188
OPPOSITIONWO2015123264

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- "WO 2005116204-A/598150: Double strand polynucleotides generating RNA interference.", EMBL, (20110420), Database accession no. FZ191625, URL: EBI, XP055418175
OPPOSITION- Anonymous J, "The Dharmacon™ Story", GELifeSciences Selected Key Dharmacon Publications, (20140401), page 1, GELifeSciences Selected Key Dharmacon Publications, (20220405), XP055909111
OPPOSITION- Anonymous, "Silencer® Select Pre-designed and Validated siRNA, In Vivo Ready Ambion® In Vivo Pre-designed and Custom Designed siRNA, In Vivo Ready or HPLC-purified Custom Select siRNA and Ambion® In Vivo Custom siRNA, In Vivo Ready", Ambion, (20101101), pages 1 - 2, Ambion, (20220405), XP055909116
OPPOSITION- Strong Susan, "Dharmacon and Leading Research Institutes Establish Global Initiative", Thermofisher, (20051006), pages 1 - 3, Thermofisher, (20220405), XP055909119
OPPOSITION- Troels Koch Et Al.,, "Quantum Mechanical Studies of DNA and LNA", Nucleic Acid Therapeutics, (20140101), vol. 24, no. 2, pages 139 - 148, XP055366884
OPPOSITION- Egli Martin, Manoharan Muthiah, "Re-Engineering RNA Molecules into Therapeutic Agents", Accounts of Chemical Research, ACS , Washington , DC, US, US , (20190416), vol. 52, no. 4, doi:10.1021/acs.accounts.8b00650, ISSN 0001-4842, pages 1036 - 1047, XP055909134
OPPOSITION- Peter Järver, Thibault Coursindel, Samir El Andaloussi, Caroline Godfrey, Matthew Ja Wood, Michael J Gait, "Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA", Molecular Therapy — Nucleic Acids, Nature Publishing Group, (20120601), vol. 1, no. 6, doi:10.1038/mtna.2012.18, ISSN 21622531, page e27, XP055210945
OPPOSITION- REYNOLDS A, ET AL, "Rational siRNA design for RNA interference.", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20040301), vol. 22, no. 3, doi:10.1038/nbt936, ISSN 1087-0156, pages 326 - 330, XP002311429
OPPOSITION- Nicholas M Snead, Rossi John J, "RNA Interference Trigger Variants: Getting the Most Out of RNA for RNA Interference-Based Therapeutics", Nucleic acid therapeutics, Mary Ann Liebert, Inc, United States, United States , doi:10.1089/nat.2012.0361, (20120601), pages 139 - 146, Nucleic acid therapeutics, (20151015), XP055221015
OPPOSITION- Frank Czauderna Melanie Fechtner Sibylle Dames Hüseyin Aygün Anke Klippel Gijsbertus J. Pronk Klaus Giese Jörg Kaufmann, "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.", Nucleic Acids Research, Oxford University Press, GB, GB , (20030601), vol. 31, no. 11, doi:10.1093/nar/gkg393, ISSN 0305-1048, pages 2705 - 2716, XP002270732
OPPOSITION- Yanfang Guo, Peng Xiao, Shufeng Lei, Feiyan Deng, Gary Guishan Xiao, Yaozhong Liu, Xiangding Chen, Liming Li, Shan Wu, Yuan Chen, Hui Jiang, Lijun Tan, Jingyun Xie, Xuezhen Zhu, Songping Liang, Hongwen Deng, "How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes", Acta Biochimica et Biophysica Sinica, Shanghai Scientific and Technical Publishers, (20080501), vol. 40, no. 5, doi:10.1111/j.1745-7270.2008.00418.x, ISSN 16729145, pages 426 - 436, XP055075994
OPPOSITION- Kay LH Wu;Chun-Ying Hung;Julie YH Chan;Chih-Wei Wu, "An increase in adenosine-5’-triphosphate (ATP) content in rostral ventrolateral medulla is engaged in the high fructose diet-induced hyperten", Journal of Biomedical Science, Kluwer Academic Publishers, Do, Do , (20140127), vol. 21, no. 1, doi:10.1186/1423-0127-21-8, ISSN 1423-0127, page 8, XP021175336
OPPOSITION- P. Cirillo, M. S. Gersch, W. Mu, P. M. Scherer, K. M. Kim, L. Gesualdo, G. N. Henderson, R. J. Johnson, Y. Y. Sautin, "Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells", Journal of the American Society of Nephrology, vol. 20, no. 3, doi:10.1681/ASN.2008060576, ISSN 10466673, pages 545 - 553, XP055187675
OPPOSITION- Naito Yuki, Ui-Tei Kumiko, "siRNA Design Software for a Target Gene-Specific RNA Interference", Frontiers in Genetics, (20120611), vol. 3, doi:10.3389/fgene.2012.00102, pages 1 - 7, XP055817712

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents